Axsome Therapeutics (AXSM) Capital Expenditures Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 143.40% |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -64.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.20% |
| Dec 31, 2025 | 136.67% |
| Sep 30, 2025 | -35.56% |
| Jun 30, 2025 | -75.00% |
| Mar 31, 2025 | 244.90% |
| Dec 31, 2024 | 328.57% |
| Sep 30, 2024 | -75.74% |
| Jun 30, 2024 | -60.90% |
| Mar 31, 2024 | 38.03% |
| Dec 31, 2023 | -96.13% |
| Sep 30, 2023 | 462.12% |
| Jun 30, 2023 | -44.81% |
| Mar 31, 2023 | -66.82% |
| Dec 31, 2022 | 40,033.04% |
| Sep 30, 2022 | -74.49% |
| Jun 30, 2022 | 1,176.69% |
| Mar 31, 2022 | 613.45% |
| Dec 31, 2021 | -97.78% |
| Sep 30, 2021 | 1,642.52% |
| Jun 30, 2021 | 1,221.92% |
| Mar 31, 2021 | 221.46% |
| Dec 31, 2020 | 1,288.57% |
| Sep 30, 2020 | 364.49% |
| Sep 30, 2019 | -62.32% |
| Sep 30, 2018 | 135.39% |
| Jun 30, 2018 | 183.92% |
| Mar 31, 2018 | 402.79% |
| Dec 31, 2017 | -99.98% |
| Sep 30, 2017 | -95.28% |
| Jun 30, 2017 | -70.74% |
| Mar 31, 2017 | -72.78% |
| Dec 31, 2016 | 47.25% |
| Sep 30, 2016 | 1,630.29% |
| Jun 30, 2016 | 716.97% |
| Mar 31, 2016 | 3.85% |